1-[4-(4-氯苯基)-1,3-噻唑-2-基]-5-(三氟甲基)吡唑-4-羧酸 | 159885-82-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-[4-(4-氯苯基)-1,3-噻唑-2-基]-5-(三氟甲基)吡唑-4-羧酸
• 英文名称: 1-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid
• 英文别名: 1-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-5-(trifluoromethyl)pyrazole-4-carboxylic acid
• CAS: 159885-82-2
• 化学式: C₁₄H₇ClF₃N₃O₂S
• 分子量: 373.743
• InChiKey: MTSSIDJMQWKVKU-UHFFFAOYSA-N

物化性质

• 熔点：
  195-198°C
• 沸点：
  558.8±60.0 °C(Predicted)
• 密度：
  1.66±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  96.2
• 氢给体数：
  1
• 氢受体数：
  8

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  1-[4-(4-氯苯基)-1,3-噻唑-2-基]-5-(三氟甲基)吡唑-4-羧酸 、 3-二乙胺基丙胺 在 N,N'-羰基二咪唑 作用下， 生成 1-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-N-[3-(diethylamino)propyl]-5-(trifluoromethyl)pyrazole-4-carboxamide
  参考文献：
  名称：

  Novel Thiazole-Based Heterocycles as Selective Inhibitors of Fibrinogen-Mediated Platelet Aggregation

  摘要：

  The synthesis and biological activity of novel thiazole-based heterocycles as inhibitors of thrombin-induced human platelet aggregation are described. Further evaluation of selected compounds show they inhibit platelet aggregation as stimulated by a variety of agonists. The more active compounds also were found to inhibit fibrinogen binding to platelets. To further delineate the mechanism of action of these compounds, direct binding studies with the purified glycoprotein (GP) IIb/IIIa receptor were performed. Flow cytometry analyses of 24 and 32 indicate that these compounds block the activation process of the GPIIb/IIIa receptor without denaturing the integrin receptor. On the basis of these studies, 32 exhibited the best profile as a novel nonpeptide inhibitor of fibrinogen-mediated platelet aggregation.

  DOI：

  10.1021/jm00001a008
• 作为产物：
  描述：

  ethyl (Z)-2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 7.0h， 生成 1-[4-(4-氯苯基)-1,3-噻唑-2-基]-5-(三氟甲基)吡唑-4-羧酸
  参考文献：
  名称：

  Novel Thiazole-Based Heterocycles as Selective Inhibitors of Fibrinogen-Mediated Platelet Aggregation

  摘要：

  The synthesis and biological activity of novel thiazole-based heterocycles as inhibitors of thrombin-induced human platelet aggregation are described. Further evaluation of selected compounds show they inhibit platelet aggregation as stimulated by a variety of agonists. The more active compounds also were found to inhibit fibrinogen binding to platelets. To further delineate the mechanism of action of these compounds, direct binding studies with the purified glycoprotein (GP) IIb/IIIa receptor were performed. Flow cytometry analyses of 24 and 32 indicate that these compounds block the activation process of the GPIIb/IIIa receptor without denaturing the integrin receptor. On the basis of these studies, 32 exhibited the best profile as a novel nonpeptide inhibitor of fibrinogen-mediated platelet aggregation.

  DOI：

  10.1021/jm00001a008

文献信息

• HETEROCYCLIC DERIVATIVE AND USE THEREOF
  申请人：Matsunaga Nobuyuki

  公开号：US20110028493A1

  公开（公告）日：2011-02-03

  The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like and useful as an sGC activation drug, or an agent for the prophylaxis and/or treatment of diseases such as hypertension, ischemic cardiac disease, cardiac failure, kidney disease, arteriosclerotic disease, atrial fibrillation, pulmonary hypertension, diabetes, diabetic complications, metabolic syndrome, peripheral arterial obstruction, erectile dysfunction and the like. An sGC activation drug containing a compound represented by the formula (II): wherein each symbol is as defined in the specification, or a salt thereof, as an active ingredient.

  本发明旨在提供一种具有优异的药理作用、物理化学性质等，并且可用作sGC激活药物、高血压、缺血性心脏病、心力衰竭、肾脏疾病、动脉硬化疾病、心房颤动、肺动脉高压、糖尿病、糖尿病并发症、代谢综合征、周围动脉阻塞、勃起功能障碍等疾病的预防和/或治疗剂的化合物。其中，所述化合物为式（II）所表示的化合物或其盐，作为活性成分的sGC激活药物。式（II）中，各符号如规范中定义的。
• Bis-aryl thiazole derivatives
  申请人：Amaral Catherine M.

  公开号：US20050215608A1

  公开（公告）日：2005-09-29

  Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by an uncoupling protein. In particular, the compounds of the invention modulate the expression and/or activity of UCP3. The subject compositions are particularly useful in the treatment of obesity and type II diabetes, and associated diseases.

  本发明提供的化合物、组合物和方法可用于治疗或预防由解偶联蛋白介导的病症或紊乱。特别是，本发明的化合物可调节 UCP3 的表达和/或活性。本发明组合物特别适用于治疗肥胖症和 II 型糖尿病及相关疾病。
• US7358267B2
  申请人：——

  公开号：US7358267B2

  公开（公告）日：2008-04-15
• US8461348B2
  申请人：——

  公开号：US8461348B2

  公开（公告）日：2013-06-11
• [EN] BIS-ARYL THIAZOLE DERIVATIVES<br/>[FR] DERIVES DE BIS-ARYL THIAZOLE
  申请人：TULARIK INC

  公开号：WO2003002062A2

  公开（公告）日：2003-01-09

  Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by an uncoupling protein. In particular, the compounds of the invention modulate the expression and/or activity of UCP3. The subject compositions are particularly useful in the treatment of obesity and type II diabetes, and associated diseases.